Why Health Is Becoming the New Currency of Wealth – and What Asia’s Private Wealth Industry Should Do About It
For most of the past three decades, private wealth in Asia has been organised around financial returns: alpha, allocation, succession, structuring. That equation is quietly being rewritten. A new generation of clients — Gen X heirs, founder-CEOs, multi-jurisdictional UHNW principals — has begun to treat health and longevity not as a personal hobby, but as a core component of family wealth, with the same weight once reserved for tax structures and trust planning. The “health is wealth” cliché has become an operating principle, and it is redrawing the competitive map across private banking, external asset management, multi-family offices, single-family offices and securities distribution.
Six Key Takeaways
1. Health has become a core component of wealth, not a lifestyle add-on: Asia’s wealthiest clients now treat healthspan with the same seriousness once reserved for tax structuring and succession planning. With Singapore’s life expectancy at 84.8 years but healthy life expectancy at only 74.2 years, the decade-long gap between living and living well has become the single most consequential variable in modern wealth planning, eroding retirement capital, complicating succession timelines and redefining what clients want their money to do.
2. The science is no longer fringe, it is credentialed, capitalised and centred in Asia: Geroscience has matured from biohacking into mainstream medical research, anchored by figures including Brian Kennedy and Andrea Maier at the NUS Centre for Healthy Longevity, Peter Attia’s Medicine 3.0 framework, David Sinclair at Harvard, and Steve Horvath’s foundational work on DNA methylation clocks. Singapore, with the NUS Academy for Healthy Longevity and its new clinical trial centre, is positioning itself as the regional hub for healthy-longevity research.
3. The economics are now serious enough to change industries: Longevity investment more than doubled in 2024 to roughly USD 8.49 billion. Altos Labs launched with USD 3 billion in backing from Jeff Bezos and Yuri Milner; Calico has received USD 3.5 billion; Sam Altman has personally committed USD 180 million to Retro Biosciences. The senolytics market alone is projected to roughly double to USD 64.8 billion by 2034, and the longevity-clinic segment is growing at 14.2 per cent annually — a real, investable opportunity, not a marketing trend.
4. Banks are already moving, and the relationship economics are unmatched: HSBC’s Premier launch in Singapore and Prestige Circle proposition through HSBC Life, the bank’s Humansa partnership in Hong Kong, and parallel initiatives at Standard Chartered, Bank of Singapore, OCBC, DBS and the Swiss houses signal a clear direction of travel. A 24/7 health concierge, an annual longevity protocol and a coaching app touch a client several times a week — orders of magnitude more than any quarterly investment review — and dramatically raise switching costs.
5. EAMs, MFOs, SFOs and securities firms can compete credibly, but they need to move now: Independent firms cannot match bank-led wellness centres on balance sheet, but they can move faster on curated partnerships with clinics such as R17, Chi Longevity, Mito Health, Prenetics, RAKxa and Clinique La Prairie; on client education programming around longevity science; and on portfolio reconstruction for a genuine 100-year life. Securities firms with credible thematic capability across GLP-1s, senolytics, biological-age diagnostics and AI-native drug discovery hold a real advantage in the conversations clients now want to have.
6. Rigour matters, this is differentiation, not decoration: The opportunity is real but the field is young. Biological-age clocks remain a work in progress, candidate compounds such as rapamycin are still being characterised in human trials, and several clinics blur the line between credentialed medicine and consumer wellness. Regulatory perimeters under MAS and HKMA are still being drawn, conflicts of interest exist wherever a wellness partner is also a commercial counterparty, and lock-in risk is real. Firms that win will be those that take a defensible position — on the science, the providers and the products — rather than those that bolt a wellness logo onto an existing proposition.
This article examines what is driving the shift and why it matters for practitioners. Longevity science has matured from fringe biohacking into a credentialed discipline led by figures such as the NUS Centre for Healthy Longevity’s Brian Kennedy and Andrea Maier, Harvard’s David Sinclair and Peter Attia. They will see how more than USD 8 billion a year is now flowing into longevity biotech and clinics. And they will see the practical implications: how relationship managers, IAMs, EAMs, MFOs, SFOs and securities firms across Asia can build a differentiated proposition before their clients’ attention drifts to the firm that thought of it first.
Ask any seasoned private banker in Hong Kong or Singapore what UHNW clients talked about a decade ago and the answers are familiar: succession, property, alternatives allocation, the next pre-IPO round. Ask the same banker today and a strikingly different theme keeps surfacing. Clients are asking about sleep scores, biological-age tests, GLP-1 protocols, longevity clinics in Switzerland and Thailand, and which heart-rate-variability device a peer has just installed. The unifying message is that the wealthiest people in the region are starting to think about time itself — not as a financial-planning input, but as the ultimate asset.
The banking industry is moving alongside that shift. HSBC Singapore’s recent launch of an integrated health, wellness and longevity proposition for Premier clients was the most visible recent move, built around an IHH Healthcare concierge, preventive screening and biological-age assessments delivered with Raffles Medical Group. It is neither the first nor the last. HSBC in Hong Kong has separately partnered with Humansa, a longevity venture launched in 2020, to design dedicated programmes for wealth clients, and within days HSBC Life Singapore introduced Prestige Circle, a HNW proposition combining external wealth-planning specialists with preventive longevity work via Chi Longevity and Raffles Medical. Standard Chartered has been embedding wellness into its private-client experience for several years. Bank of Singapore, OCBC, DBS Treasures Private Client and most of the Swiss houses in Asia are running pilots, hosting longevity-themed client events, or formalising relationships with biological-age testing providers. The direction of travel is clear.
The underlying driver is a generational reframing of what wealth is for. Internal research that banks cite suggests personal and family wellness now ranks alongside travel and lifestyle as a top spending priority for affluent Singaporeans, and ahead of luxury goods. The figure that anchors the entire conversation is the gap between lifespan and healthspan. Average life expectancy in Singapore now stands at 84.8 years, but healthy life expectancy is only 74.2 years — more than a decade of preventable decline. That gap is the most consequential statistic in modern wealth planning. It is the gap that quietly erodes retirement capital, derails succession timelines, complicates intergenerational transfer, and increasingly defines what clients want their money to do.
Crucially, the science underneath the trend is no longer fringe. At the National University of Singapore, Professor Brian Kennedy — a foundational figure in geroscience and former CEO of the Buck Institute for Research on Aging — leads the Centre for Healthy Longevity, where human trials of rapamycin are testing whether one of the most-discussed candidate compounds can meaningfully slow biological ageing. Alongside him, Professor Andrea Maier, Oon Chiew Seng Professor in Medicine and director of the NUS Academy for Healthy Longevity, has built an interdisciplinary gerodiagnostics framework that integrates molecular, clinical, behavioural and social biomarkers of ageing. A new clinical trial centre opened under the Academy in late 2025, with major research partners including Haleon and Abbott. Globally, the field’s public-facing voices include Peter Attia, whose 2023 book Outlive has sold around 1.5 million copies and whose Early Medical practice popularised what he calls Medicine 3.0; Harvard’s David Sinclair on cellular reprogramming; Steve Horvath, whose DNA methylation clock essentially created the field of biological-age estimation; Eric Verdin at the Buck Institute; and Cynthia Kenyon, now at Calico.
The economics behind the science are increasingly serious. Investment in longevity biotechnology and diagnostics more than doubled in 2024 to roughly USD 8.49 billion. Altos Labs, backed by Jeff Bezos and Yuri Milner, launched in 2022 with a USD 3 billion war chest to pursue cellular reprogramming. Calico, Alphabet’s longevity arm, has received around USD 3.5 billion in cumulative funding. Retro Biosciences, backed by OpenAI’s Sam Altman with roughly USD 180 million of personal capital, is pursuing autophagy and reprogramming work. The longevity biotech and senolytics market alone was valued at USD 31.6 billion in 2025 and is projected to reach USD 64.8 billion by 2034, while broader geroscience estimates see the wider market expanding from around USD 20 billion in 2024 to USD 200 billion by 2030. These are not eccentric numbers — they are the kind of capital flows that change industries.
The fastest-growing slice of this economy is the one wealth clients touch directly: longevity clinics. The clinic segment is projected to grow at a 14.2 per cent compound annual rate through 2034, driven by direct-to-consumer demand for biological-age testing, NAD+ infusions, hormone optimisation and lifestyle protocols. Asia is in the middle of this expansion. Singapore alone now hosts Chi Longevity, Raffles Medical’s R17, Mito Health and Prenetics, alongside the world’s first public longevity clinic launched by NUHS at Alexandra Hospital. Switzerland’s Clinique La Prairie, the lakeside institution that pioneered the modern luxury longevity clinic, is opening new destinations in Phuket and the Red Sea in autumn 2026, having already established a Longevity Hub in Bangkok and a resort in Anji, China. RAKxa in Thailand, COMO Shambhala, Aleenta and Six Senses’ integrated wellness programmes across Indonesia, Thailand and Vietnam service similar clientele. Newer entrants such as Helix Privé are bundling biohacking, regenerative therapies and concierge wellness into private-member offerings for global UHNW families. Pricing for week-long residential programmes at the top tier runs from roughly USD 10,000 to USD 52,000.
For Asia’s private wealth industry, the strategic question is no longer whether to engage with this trend but how to do so without being merely decorative. There are three reasons “health is wealth” is now a genuine differentiator rather than a marketing veneer. First, the relationship economics are unmatched. A 24/7 health concierge, an annual longevity protocol and a coaching app touch a client several times a week — orders of magnitude more often than any quarterly investment review. Switching costs rise sharply when screening history, a spouse’s wellness plan and a parent’s admission records all sit within the same proposition. Second, it speaks directly to the intergenerational question every wealth firm wrestles with. Rising-gen family members engage on healthspan when they will not engage on rebalancing — and the firm that earns that conversation early often wins the relationship through transition. Third, it elevates the adviser from product distributor to life curator: harder to commoditise, more defensible against fee compression, and more central to family decision-making.
For external asset managers, multi-family offices and single-family offices, the playbook is different but no less significant. Independent firms cannot match the balance sheets that bankroll bank-led wellness centres, but they can move faster and more credibly into curated partnerships. The most effective propositions combine three elements: referral relationships with leading clinics — R17, Chi Longevity, Mito Health, Prenetics, RAKxa, Clinique La Prairie — negotiated as benefits for clients; sustained content and education programming on longevity science, biological-age testing and the financial consequences of a 100-year life; and a meaningful rethink of portfolio construction. Traditional wealth planning was built around assumed lifespans of 70 to 80 years and is poorly suited to clients who may live well into their 90s. Longer horizons mean more equity duration, more inflation-linked assets, more weight given to long-term care and chronic disease as real liabilities, and a fresh look at trust and insurance structures.
Securities firms and product distributors face a parallel opportunity. Healthcare, biotech, medtech, AI-enabled diagnostics and the broader longevity thematic are no longer niche allocations. GLP-1 agonists, senolytics, biological-age diagnostics businesses such as TruDiagnostic, and AI-native discovery platforms such as Insilico Medicine compressing drug-discovery timelines are areas in which UHNW clients now have a direct personal stake. A fund selector who can credibly discuss Yamanaka factors, mitochondrial dysfunction, autophagy or epigenetic clocks holds an edge in the conversations clients actually want to have. The thematic fund, feeder and direct co-investment opportunity is real and likely to grow rapidly.
The insurance and wealth-planning side will feel this too. As lifespans extend and chronic disease becomes the dominant later-life financial risk, the underwriting case for variable universal life, indexed universal life and dedicated long-term care products strengthens. So does the case for wellness-linked policies that price client behaviour into premiums. Trusts, family constitutions and succession frameworks designed for shorter horizons need reopening. Estate planners will be asked to model scenarios in which the wealth creator lives to 95 in vigorous health, turning what was once a tax-and-transfer exercise into a multi-decade living-wealth conversation.
None of this is without caveats. The science is promising but young. Biological-age clocks remain a work in progress and the dose, timing and effect of candidate compounds such as rapamycin are still being characterised in human trials. Several high-profile clinics blur the line between credentialed medicine and consumer wellness, and not every intervention on offer survives scrutiny. Competing voices within the field — Attia and Sinclair on one side, more sceptical clinicians on the other — should remind any adviser to maintain rigour. Regulatory perimeters around banking concierge services, healthcare referrals and patient data are still being drawn under MAS, HKMA and the relevant health authorities. Conflicts of interest will emerge wherever a wellness partner is also a sponsor or commercial counterparty. And there is the perennial question of whether such offerings genuinely serve the client or quietly increase lock-in.
The professionals most likely to navigate this well are those who treat health and longevity as part of holistic advisory rather than as a marketing layer. That means relationship managers being trained to ask not only about asset allocation but about sleep, mobility, screening history and family medical context — and being equipped to refer credibly when the answers warrant. It means investment committees treating longevity risk as a real input into asset-liability matching. It means succession planning that begins not at age 70 but at age 50. And it means firms taking a position — on the science, on the providers, and on the products — they are prepared to put their name behind.
The competitive frontier in Asian private wealth has shifted beyond returns, access and digital experience. It now extends into the quality and length of the client’s life. The banks moving first have understood this; the wider industry — IAMs, EAMs, MFOs, SFOs and securities firms — should be careful not to be left behind. For those who get the proposition right, the prize is the most valuable thing in this business: a client relationship anchored not in product, but in time itself.
